CureMatch specializes in precision medicine, particularly in the field of oncology, by providing oncologists with advanced tools for personalized cancer treatment. Their platform utilizes proprietary algorithms to analyze a vast array of genomic, historical, and patient-specific data, enabling the ranking and scoring of combination therapies tailored to individual cancer profiles. This approach is designed to enhance treatment outcomes, as evidenced by significant improvements in progression-free survival (PFS) for a majority of patients receiving therapies based on high matching scores. The integration of proteomic and genomic data from formalin-fixed, paraffin-embedded (FFPE) tissue samples further enriches the molecular understanding of a patient's cancer, allowing for more informed treatment decisions.

Additionally, CureMatch has been recognized for its innovative approach with the granting of CPT Code 0794T, which facilitates the reimbursement process for oncologists utilizing their therapy matching services. This code, effective from July 1, 2023, underscores the growing acceptance and integration of precision treatment options in clinical practice. By providing clear, actionable reports that outline ranked drug therapies based on genomic data, CureMatch empowers healthcare providers to make informed decisions that align with the unique characteristics of each patient's cancer, ultimately aiming to improve the efficacy of cancer treatments.

United States

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

CureMatch

Company Details